Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 200

1.

Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials.

Jiang Y, Sun X, Kong B, Jiang J.

Medicine (Baltimore). 2018 Aug;97(34):e11920. doi: 10.1097/MD.0000000000011920.

2.

PCNA-associated factor P15PAF , targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients.

Jin C, Liu Z, Li Y, Bu H, Wang Y, Xu Y, Qiu C, Yan S, Yuan C, Li R, Diao N, Zhang Z, Wang X, Liu L, Kong B.

Int J Cancer. 2018 Aug 21. doi: 10.1002/ijc.31800. [Epub ahead of print]

PMID:
30129654
3.

Diagnostic accuracy of frozen section analysis of borderline ovarian tumors: a meta-analysis with emphasis on misdiagnosis factors.

Huang Z, Li L, Li C, Ngaujah S, Yao S, Chu R, Xie L, Yang X, Zhang X, Liu P, Jiang J, Zhang Y, Cui B, Song K, Kong B.

J Cancer. 2018 Jul 16;9(16):2817-2824. doi: 10.7150/jca.25883. eCollection 2018.

4.

Negative roles of B7-H3 and B7-H4 in the microenvironment of cervical cancer.

Han S, Wang Y, Shi X, Zong L, Liu L, Zhang J, Qian Q, Jin J, Ma Y, Cui B, Yang X, Kong B, Zhang Y.

Exp Cell Res. 2018 Oct 1;371(1):222-230. doi: 10.1016/j.yexcr.2018.08.014. Epub 2018 Aug 9.

PMID:
30099052
5.

miR-652 Promotes Tumor Proliferation and Metastasis by Targeting RORA in Endometrial Cancer.

Sun X, Dongol S, Qiu C, Xu Y, Sun C, Zhang Z, Yang X, Zhang Q, Kong B.

Mol Cancer Res. 2018 Aug 9. doi: 10.1158/1541-7786.MCR-18-0267. [Epub ahead of print]

PMID:
30093563
6.

53BP1 inhibits the migration and regulates the chemotherapy resistance of ovarian cancer cells.

Hong S, Li X, Zhao Y, Yang Q, Kong B.

Oncol Lett. 2018 Jun;15(6):9917-9922. doi: 10.3892/ol.2018.8596. Epub 2018 Apr 27.

7.

Anti-angiogenesis effect of Neferine via regulating autophagy and polarization of tumor-associated macrophages in high-grade serous ovarian carcinoma.

Zhang Q, Li Y, Miao C, Wang Y, Xu Y, Dong R, Zhang Z, Griffin BB, Yuan C, Yan S, Yang X, Liu Z, Kong B.

Cancer Lett. 2018 Sep 28;432:144-155. doi: 10.1016/j.canlet.2018.05.049. Epub 2018 Jun 5.

PMID:
29879497
8.

Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer.

Hou D, Liu Z, Xu X, Liu Q, Zhang X, Kong B, Wei JJ, Gong Y, Shao C.

Redox Biol. 2018 Jul;17:99-111. doi: 10.1016/j.redox.2018.03.016. Epub 2018 Mar 30.

9.

Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.

Qiu C, Wang Y, Wang X, Zhang Q, Li Y, Xu Y, Jin C, Bu H, Zheng W, Yang X, Lu N, Kong B.

Int J Oncol. 2018 Jun;52(6):2041-2050. doi: 10.3892/ijo.2018.4360. Epub 2018 Apr 4.

PMID:
29620196
10.

FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.

Wang Y, Qiu C, Lu N, Liu Z, Jin C, Sun C, Bu H, Yu H, Dongol S, Kong B.

Int J Oncol. 2018 Jun;52(6):2130-2142. doi: 10.3892/ijo.2018.4359. Epub 2018 Apr 4.

PMID:
29620165
11.

Hypocrellin B-loaded, folate-conjugated polymeric micelle for intraperitoneal targeting of ovarian cancer in vitro and in vivo.

Li J, Yao S, Wang K, Lu Z, Su X, Li L, Yuan C, Feng J, Yan S, Kong B, Song K.

Cancer Sci. 2018 Jun;109(6):1958-1969. doi: 10.1111/cas.13605. Epub 2018 May 7.

12.

Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo.

Yao S, Li L, Su XT, Wang K, Lu ZJ, Yuan CZ, Feng JB, Yan S, Kong BH, Song K.

J Exp Clin Cancer Res. 2018 Feb 26;37(1):29. doi: 10.1186/s13046-018-0700-z.

13.

miR-494 inhibits cervical cancer cell proliferation through upregulation of SOCS6 expression.

Cheng L, Kong B, Zhao Y, Jiang J.

Oncol Lett. 2018 Mar;15(3):3075-3080. doi: 10.3892/ol.2017.7651. Epub 2017 Dec 19.

14.

Prognostic value of HE4 in patients with ovarian cancer.

Yuan C, Li R, Yan S, Kong B.

Clin Chem Lab Med. 2018 Jun 27;56(7):1026-1034. doi: 10.1515/cclm-2017-1176. Review.

PMID:
29420303
15.

SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer.

Xu Y, Miao C, Jin C, Qiu C, Li Y, Sun X, Gao M, Lu N, Kong B.

Exp Cell Res. 2018 Feb 15;363(2):160-170. doi: 10.1016/j.yexcr.2017.12.029. Epub 2018 Jan 2.

PMID:
29305171
16.

A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIA cervical cancer.

Xie X, Song K, Cui B, Jiang J, Yang X, Kong B.

Int J Clin Oncol. 2018 Jun;23(3):522-531. doi: 10.1007/s10147-017-1225-8. Epub 2018 Jan 3.

PMID:
29299705
17.

Effective treatment of a patient with stage IV ovarian cancer: A case report.

Huang Z, Yan H, Chavan D, Yuan Z, Yang X, Zhang Y, Song K, Kong B.

Oncol Lett. 2018 Jan;15(1):588-591. doi: 10.3892/ol.2017.7285. Epub 2017 Oct 30.

18.

The selected biomarker analysis in 5 types of uterine smooth muscle tumors.

Zhang Q, Kanis MJ, Ubago J, Liu D, Scholtens DM, Strohl AE, Lurain JR, Shahabi S, Kong B, Wei JJ.

Hum Pathol. 2018 Jun;76:17-27. doi: 10.1016/j.humpath.2017.12.005. Epub 2017 Dec 16.

PMID:
29258902
19.

Reduced m6A mRNA methylation is correlated with the progression of human cervical cancer.

Wang X, Li Z, Kong B, Song C, Cong J, Hou J, Wang S.

Oncotarget. 2017 Oct 24;8(58):98918-98930. doi: 10.18632/oncotarget.22041. eCollection 2017 Nov 17.

20.

Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer.

Chavan DM, Huang Z, Song K, Parimi LRH, Yang XS, Zhang X, Liu P, Jiang J, Zhang Y, Kong B, Li L.

Medicine (Baltimore). 2017 Oct;96(42):e7935. doi: 10.1097/MD.0000000000007935.

Supplemental Content

Loading ...
Support Center